<DOC>
	<DOCNO>NCT02817633</DOCNO>
	<brief_summary>This multicenter , open-label , first-in-human Phase 1 study evaluate anti-TIM-3 ( T cell immunoglobulin mucin contain protein-3 ) antibody TSR-022 , monotherapy combination anti-PD-1 antibody , patient advance solid tumor limit available treatment option . The study conduct 2 part : dose escalation cohort expansion .</brief_summary>
	<brief_title>A Phase 1 Study TSR-022 , Anti-TIM-3 Monoclonal Antibody , Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Partial Patient advance metastatic solid tumor disease progression treatment intolerance treatment available therapy Agreement biopsy treatment , depend study part Female patient must negative serum pregnancy test nonchildbearing potential . Two method contraception require male female childbearing potential Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 adequate organ function Partial Received prior therapy antiCTLA4 , antiPD1 , antiPD1ligand1 ( antiPDL1 ) , antiPD1 ligand2 ( antiPDL2 ) agent within 8 week prior initiation study treatment depend study part Known uncontrolled central nervous system ( CNS ) metastases and/or carcinomatous meningitis know malignancy progress require active treatment within last 2 year Pregnant , breastfeeding , expect conceive child within project duration study History human immunodeficiency virus ( HIV ) , interstitial lung disease , active Hepatitis B Hepatitis C Autoimmune disease require systemic treatment past 2 year Not recover radiation chemotherapyinduced AEs receive blood transfusion Participated another investigational study ( drug device ) within 4 week first dose Received prior anticancer therapy within 21 day first dose Not recover AEs and/or complication major surgery prior first dose Received vaccine within 7 day first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anitibodies</keyword>
	<keyword>TSR-022</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>PD-1</keyword>
	<keyword>Anti-PD-1</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Nivolumab</keyword>
</DOC>